Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ARDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 49.72M
March 31, 2026 5.442M
December 31, 2025 0.557M
September 30, 2025 2.814M
June 30, 2025 49.66M
March 31, 2025 1.482M
December 31, 2024 49.31M
September 30, 2024 2.697M
June 30, 2024 1.608M
March 31, 2024 52.97M
December 31, 2023 25.99M
September 30, 2023 57.87M
June 30, 2023 11.52M
March 31, 2023 50.92M
December 31, 2022 18.79M
September 30, 2022 34.48M
June 30, 2022 22.14M
March 31, 2022 -0.063M
December 31, 2021 14.51M
September 30, 2021 4.999M
June 30, 2021 28.72M
March 31, 2021 34.77M
December 31, 2020 21.18M
September 30, 2020 0.798M
June 30, 2020 0.204M
Date Value
March 31, 2020 0.591M
December 31, 2019 155.06M
September 30, 2019 0.213M
June 30, 2019 0.005M
March 31, 2019 0.20M
December 31, 2018 -0.001M
September 30, 2018 0.191M
June 30, 2018 103.06M
March 31, 2018 0.301M
December 31, 2017 0.01M
September 30, 2017 0.049M
June 30, 2017 0.218M
March 31, 2017 0.408M
December 31, 2016 0.027M
September 30, 2016 109.87M
June 30, 2016 0.188M
March 31, 2016 81.12M
December 31, 2015 0.014M
September 30, 2015 -0.003M
June 30, 2015 74.70M
March 31, 2015 0.296M
December 31, 2014 0.066M
September 30, 2014 0.003M
June 30, 2014
March 31, 2014

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
REGENXBIO, Inc. 17.57M
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M
Savara, Inc. 0.189M